Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

February 02, 2006 09:00 ET

Holmes Acquiring US Clinical Research Facility

SCOTTSDALE, ARIZONA--(CCNMatthews - Feb. 2, 2006) - Holmes Herbs, Inc., (OTCBB:HMHB), announced today that its subsidiary, Qualia Clinical Service, Inc. ("Qualia") has completed a letter of intent for a clinical research facility located in Omaha, Nebraska.

The facility includes 23,000 sq. feet of leased space, with a capacity of 140 beds, capable of generating up to $1 million per month in revenue. It is projected to be completed and operating in April, 2006.

"This is a step to becoming a leader in the clinical research industry. Our facility will provide quality services to major pharmaceutical companies." said Dr. Sohail Khattak, Chief Executive Officer and President of Qualia.

About Qualia:

Qualia Clinical Service, Inc. is a subsidiary company of Holmes Herbs, Inc.. Our strategy is to become a leader in contract drug research by providing integrated and cost-effective clinical development services to the pharmaceutical industry. We also plan to become a known entity in the drug development industry.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information